Copyright
©The Author(s) 2018.
World J Diabetes. Feb 15, 2018; 9(2): 53-58
Published online Feb 15, 2018. doi: 10.4239/wjd.v9.i2.53
Published online Feb 15, 2018. doi: 10.4239/wjd.v9.i2.53
Predictor variable | Hemoglobin A1C | Random blood glucose | ||||||
Coefficient | Confidence interval | P value | Coefficient | Confidence interval | P value | |||
Sex | -0.12 | -0.60 | 0.36 | 0.63 | 1.75 | -3.80 | 7.30 | 0.54 |
Age | 0.00 | -0.01 | 0.02 | 0.71 | 0.00 | -0.16 | 0.15 | 0.98 |
Diabetes | 0.10 | -0.20 | 0.40 | 0.50 | 0.02 | -3.33 | 3.36 | 0.99 |
Malignancy | -0.20 | -0.50 | 0.09 | 0.17 | 0.54 | -3.31 | 4.39 | 0.78 |
Coronary artery disease | 0.07 | -0.30 | 0.43 | 0.72 | -1.48 | -6.54 | 3.58 | 0.57 |
Congestive heart failure | -0.07 | -0.37 | 0.22 | 0.62 | 4.69 | 0.45 | 8.92 | 0.03 |
Chronic lung disease | 0.14 | -0.11 | 0.38 | 0.27 | -0.95 | -4.16 | 2.27 | 0.56 |
Chronic kidney disease | -0.35 | -0.78 | 0.07 | 0.11 | -5.57 | -12.67 | 1.52 | 0.12 |
Hypertension | 0.01 | -0.35 | 0.38 | 0.95 | -0.81 | -4.50 | 2.88 | 0.67 |
Medication (comparator is methotrexate) | ||||||||
Adalimumab | 0.17 | -0.28 | 0.62 | 0.46 | -0.87 | -6.83 | 5.09 | 0.78 |
Golimumab | -0.56 | -1.81 | 0.70 | 0.39 | -19.88 | -44.57 | 4.82 | 0.12 |
Certolizumab | 0.41 | -2.06 | 2.87 | 0.75 | -7.02 | -46.55 | 32.51 | 0.73 |
Infliximab | -0.30 | -0.90 | 0.30 | 0.32 | -3.85 | -11.76 | 4.06 | 0.34 |
Etanercept | -0.08 | -0.56 | 0.40 | 0.75 | -2.07 | -7.97 | 3.84 | 0.49 |
Leflunomide | 0.05 | -0.37 | 0.47 | 0.81 | -2.66 | -8.68 | 3.36 | 0.39 |
Hydroxychloroquine | -0.01 | -0.36 | 0.33 | 0.94 | -5.78 | -10.38 | -1.17 | 0.01 |
Sulfasalazine | -0.58 | -1.00 | -0.16 | 0.01 | -2.56 | -8.26 | 3.15 | 0.38 |
Prednisone | 0.11 | -0.26 | 0.49 | 0.55 | 3.76 | -0.82 | 8.34 | 0.11 |
Medication class (comparator is conventional DMARDs) | ||||||||
TNFi | 0.06 | -0.23 | 0.35 | 0.68 | 0.30 | -3.47 | 4.07 | 0.88 |
Glucocorticoid | 0.20 | -0.13 | 0.53 | 0.23 | 6.32 | 2.40 | 10.24 | < 0.01 |
- Citation: Wood PR, Manning E, Baker JF, England B, Davis L, Cannon GW, Mikuls TR, Caplan L. Blood glucose changes surrounding initiation of tumor-necrosis factor inhibitors and conventional disease-modifying anti-rheumatic drugs in veterans with rheumatoid arthritis. World J Diabetes 2018; 9(2): 53-58
- URL: https://www.wjgnet.com/1948-9358/full/v9/i2/53.htm
- DOI: https://dx.doi.org/10.4239/wjd.v9.i2.53